ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1801 • 2013 ACR/ARHP Annual Meeting

    Relationship Between MRI and Clinical Remission In Patients With Non-Radiographic Axial Spondyloarthritis After Two Years Of Adalimumab Therapy

    Désiréé van der Heijde1, Walter P. Maksymowych2, Joachim Sieper3, Robert Lambert4, Matthew A. Brown5, Suchitrita S. Rathmann6, Jaclyn K. Anderson6 and Aileen L. Pangan6, 1Leiden University Medical Center, Leiden, Netherlands, 2Medicine, University of Alberta, Edmonton, AB, Canada, 3Charité University Medicine Berlin, Berlin, Germany, 4Radiology, University of Alberta Hospital, Edmonton, AB, Canada, 5Translational Research Institute, University of Queensland Diamantina Institute, Brisbane, Australia, 6AbbVie Inc., North Chicago, IL

    Background/Purpose: Adalimumab (ADA) is currently approved in the EU for the treatment of severe non-radiographic axial spondyloarthritis (nr-axSpA), in patients (pts) with an elevated CRP…
  • Abstract Number: 1802 • 2013 ACR/ARHP Annual Meeting

    A Major Clinical Response To Anti-Tumor Necrosis Factor Agents Is Associated With a Reduced Development Of Fatty Changes In The Spine Of Patients With Ankylosing Spondylitis

    Xenofon Baraliakos1, Frank Heldmann2, Joachim Listing3, Johanna Callhoff3 and Jürgen Braun2, 1Rheumatology, Rheumazentrum Ruhrgebiet, Herne, Germany, 2Rheumazentrum Ruhrgebiet, Herne, Germany, 3German Rheumatism Research Center, Berlin, Germany

    Background/Purpose: Fatty changes (FC) on T1-weighted magnetic resonance images (MRI) have been described in the spine of patients with ankylosing spondylitis (AS). Such lesions were…
  • Abstract Number: 1803 • 2013 ACR/ARHP Annual Meeting

    Is Site Of Back Pain Related To Location Of Inflammatory and Structural Lesions On MRI In Patients With Chronic Back Pain?

    Manouk de Hooge1, Rosaline van den Berg2, Floris van Gaalen2, Victoria Navarro-Compán2, Monique Reijnierse3, Karen Fagerli4, Maureen C. Turina5, Maikel van Oosterhout6, Roberta Ramonda7, Tom Huizinga2 and Désirée van der Heijde1, 1Leiden University Medical Center, Leiden, Netherlands, 2Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 3Radiology, Leiden University Medical Center, Leiden, Netherlands, 4Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 5Department of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, 6Rheumatology, GHZ Hospital, Gouda, Netherlands, 7Rheumatology Unit, University of Padova, Padova, Italy

    Background/Purpose: Pain has found to be related to inflammatory lesions in thoracic, lumbar and sacroiliac joints (SIJ) sites and to structural lesions in the SIJ…
  • Abstract Number: 1804 • 2013 ACR/ARHP Annual Meeting

    Effect of Mycophenolate On the White Blood Cell Count and the Frequency of Infection in Systemic Lupus Erythematosus

    Ananta Subedi1, Hong Fang2 and Michelle Petri2, 1Good Samaritan Hospital, Baltimore, MD, 2Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Leukopenia is a common manifestation of SLE. Addition of immunosuppressive therapy is of concern, in that it could worsen leukopenia; increase the risk of…
  • Abstract Number: 1806 • 2013 ACR/ARHP Annual Meeting

    Association Between Hydroxychloroquine Exposure and Incidence Of Diabetes Mellitus In Systemic Lupus Erythematosus

    Michelle Petri1 and Laurence S. Magder2, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD

    Background/Purpose: Diabetes mellitus is one of the SLICC/ACR Damage Index items and a recognized risk factor for cardiovascular disease and renal failure.  In rheumatoid arthritis,…
  • Abstract Number: 1807 • 2013 ACR/ARHP Annual Meeting

    Do We Know How and When To Taper and Stop In Immunosuppressants In Lupus Patients?

    Zahi Touma1, Murray B. Urowitz2, Dominique Ibanez2 and Dafna D. Gladman2, 1Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose: After achieving low disease activity or remission, immunosuppressant therapies might be stopped in lupus patients, but information on whether and how this should be…
  • Abstract Number: 1768 • 2013 ACR/ARHP Annual Meeting

    Value Of Arthroscopic Partial Meniscectomy In Treatment Of Symptomatic Patients With Meniscal Tears and Knee Osteoarthritis: Is More Research Warranted?

    Elena Losina1, A. David Paltiel2, Elizabeth Dervan1, Yan Dong1, Kurt P. Spindler3, Lisa A. Mandl4, Morgan Jones5, John Wright6 and Jeffrey N. Katz7, 1Orthopaedic and Arthritis Center for Outcomes Research, Brigham and Women's Hospital, Boston, MA, 2Yale School of Public Health, New Haven, CT, 3Vanderbilt University, Nashville, TN, 4Rheumatology, Hospital for Special Surgery, New York, NY, 5Orthopedic Surgery, Cleveland Clinic, Cleveland, OH, 6Orthopedic Surgery, Brigham and Women's Hospital, Boston, MA, 7Rheumatology and Orthopedics, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Arthroscopic partial meniscectomy (APM) is often offered to patients with symptomatic meniscal tear (MT). Recent trials in symptomatic patients with MT and knee OA…
  • Abstract Number: 1769 • 2013 ACR/ARHP Annual Meeting

    Direct and Indirect Costs For Patients With Systemic Lupus Erythematosus In National Cohorts In Sweden

    Andreas Jönsen1, Anders A. Bengtsson1, Christine Bengtsson2, Iva Gunnarsson3, Johanna Gustafsson3, Frida Hjalte4, Dag Leonard5, Susanne Pettersson3, Solbritt Rantapää Dahlqvist6, Lars Rönnblom7, Christopher Sjöwall8, Katarina Steen Carlsson9, Elisabet Svenungsson10, Minna Willim11 and Ola Nived12, 1Department of Clinical Sciences, Section of Rheumatology, Lund University, Lund, Sweden, 2Dpt of Public Health and Clinical Medicine, Umeå University, Rheumatology, Umeå, Sweden, 3Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, 4The Swedish Institute for Health Economics,, Health Economy, Lund, Sweden, 5Department of Medical Sciences, SciLife Lab, Rheumatology, Uppsala University, Uppsala, Sweden, Uppsala, Sweden, 6Department of Public Health and Clinical Medicine/Rheumatology, Umeå University Hospital, Umeå, Sweden, 7Department of Medical Sciences, Section of Rheumatology, Uppsala University, Uppsala, Sweden, 8Deparment of clinical and experimental medicine, Linköping University, Linköping, Sweden, 9The Swedish Institute of Health Economics, Health Economy, Lund, Sweden, 10Department of Medicine, Unit of Rheumatology, Karolinska Institutet, Stockholm, Sweden, 11Department of Clinical Sciences Malmö, Section of Rheumatology, Lund University, Malmö, Sweden, 12Department of Clinical Science, Lund University, Rheumatology, Lund, Sweden

    Background/Purpose: To study direct and indirect costs for patients with Systemic Lupus Erythematosus (SLE) ín five defined cohorts with nationwide spread in Sweden, and to…
  • Abstract Number: 1770 • 2013 ACR/ARHP Annual Meeting

    All-Cause Mortality For Patients with Rheumatoid Arthritis In a Universal Public Health Care System

    Jessica Widdifield1,2, J. Michael Paterson1, Sasha Bernatsky3, Bindee Kuriya4, J. Carter Thorne5, Simon Hollands1 and Claire Bombardier6, 1Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, 2University of Toronto, Toronto, ON, Canada, 3McGill University, Montreal, QC, Canada, 4Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 5Southlake Regional Health Centre, Newmarket, ON, Canada, 6Rheumatology, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Studies evaluating trends in rheumatoid arthritis (RA) mortality over time have produced inconsistent results. Our aim was to estimate all-cause mortality in RA between…
  • Abstract Number: 1771 • 2013 ACR/ARHP Annual Meeting

    Cost-Effectiveness Of Different Treatment Sequences Including Adalimumab In The Treat-To-Target Framework For Early Rheumatoid Arthritis In Germany

    Malte Wolff1, Zheng-Yi Zhou2, James Signorovitch2, James W. Shaw3 and Arijit Ganguli3, 1AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, 2Analysis Group, Inc., Boston, MA, 3AbbVie Inc., North Chicago, IL

    Background/Purpose: The 2012 German rheumatoid arthritis (RA) treatment guidelines recommend sequential use of disease-modifying antirheumatic drugs (DMARDs) in a treat-to-target (T2T) framework. Biologics are recommended…
  • Abstract Number: 1772 • 2013 ACR/ARHP Annual Meeting

    Better Cost-Effectiveness and Worker Productivity In Triple DMARD Therapy Versus Methotrexate Monotherapy In Early Rheumatoid Arthritis; Cost-Utility Analysis Of The Treach Trial

    P.H.P. de Jong1, A.E.a.M. Weel2, J.J. Luime3, P.J. Barendregt2, A.H. Gerards4, P.A. van der Lubbe4, M.H. de Jager5, P.B. de Sonnaville6, D. van Zeben7, B.A. Grillet8 and J.M.W. Hazes3, 1Department of Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, 2Department of Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, 3Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, 4Department of Rheumatology, Vlietland Hospital, Schiedam, Netherlands, 5Department of Rheumatology, Albert Schweitzer Hospital, Dordrecht, Netherlands, 6Department of Rheumatology, Admiraal de Ruyter hospital, Goes, Netherlands, 7Department of Rheumatology, Sint Franciscus Gasthuis, Rotterdam, Netherlands, 8Department of Rheumatology, Zorgsaam Hospital, Terneuzen, Netherlands

    Background/Purpose: In the treatment in the Rotterdam Early Arthritis Cohort (tREACH) trial we showed that treatment goals were attained faster and  maintained with less treatment…
  • Abstract Number: 1773 • 2013 ACR/ARHP Annual Meeting

    The Contribution Of Environmental Factors To Familial Risk Of Rheumatoid Arthritis By Serologic Phenotypes Among Women In a Longitudinal Cohort Study

    Jeffrey A. Sparks1, Chia-Yen Chen2, Linda T. Hiraki3, Susan Malspeis4, Karen H. Costenbader4 and Elizabeth W. Karlson1, 1Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 2Epidemiology, Harvard School of Public Health, Boston, MA, 3Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard School of Public Health, Boston, MA, 4Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: Familial risk of RA is composed of shared genetic and environmental factors. Previous studies exploring familial risk of RA have not incorporated environmental factors…
  • Abstract Number: 1774 • 2013 ACR/ARHP Annual Meeting

    Sepsis Is The Leading Cause Of Hospital Mortality In Dermatomyositis/Polymyositis: Data From a Population-Based Study

    Sara Murray1, Laura Trupin1, Chris Tonner1, Matthew Cascino1, Gabriela Schmajuk1, Mary Margaretten2, Jennifer Barton1, Patricia P. Katz1, Edward H. Yelin3 and Jinoos Yazdany1, 1Medicine, University of California, San Francisco, San Francisco, CA, 2Rheumatology, University of California, San Francisco, San Francisco, CA, 3Medicine, UC San Francisco, San Francisco, CA

    Background/Purpose:   Dermatomyositis (DM) and polymyositis (PM) are debilitating inflammatory myopathies with five-year mortality rates estimated to be 33%.  However, the leading causes of inpatient…
  • Abstract Number: 1775 • 2013 ACR/ARHP Annual Meeting

    Use Of “Computer-Aided Lung Informatics For Pathology Evaluation and Rating” Software In High-Resolution Computed Tomography In Patients With Idiopathic Inflammatory Myopathy and Interstitial Lung Disease

    Katelynn Wilton1, Brian Bartholmai2, Sanjay Kalra3, Cynthia S. Crowson4, Helen Khun4 and Floranne C. Ernste5, 1Mayo Clinic College of Medicine, Rochester, MN, 2Thoracic Radiology, Mayo Clinic, Rochester, MN, 3Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, 4Department of Health Sciences Research, Mayo Clinic, Rochester, MN, 5Division of Rheumatology, Mayo Clinic Rochester, Rochester, MN

    Background/Purpose: The idiopathic inflammatory myopathies (IIM) are associated with interstitial lung disease (ILD), characterized by parenchymal abnormalities on high-resolution computed tomography (HRCT). We determined the…
  • Abstract Number: 1776 • 2013 ACR/ARHP Annual Meeting

    Peripheral Blood Memory B Cell Numbers Predict Clinical Response Following Rituximab Treatment Of Adult and Childhood Myositis

    Rohit Aggarwal1, Chester V. Oddis2, Erich R Wilkerson3, Diane Koontz4, Ilinca D. Metes5, Ann M. Reed6, Dana P. Ascherman7 and Marc C. Levesque8, 1Medicine / Rheumatology, University of Pittsburgh, Pittsburgh, PA, 2Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 3Medicine, University of Pittsburgh, Pittsburgh, PA, 4Department of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 5Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Pittsburgh, Pittsburgh, PA, 6Rheumatology, Mayo Clinic, Rochester, MN, 7Medicine/Rheumatology, University of Miami Miller School of Medicine, Miami, FL, 8Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: B cell subset numbers, especially lower memory B (Bmem) cells, predict clinical responsiveness to rituximab in several diseases including pemphigus and rheumatoid arthritis (RA).…
  • « Previous Page
  • 1
  • …
  • 2130
  • 2131
  • 2132
  • 2133
  • 2134
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology